Member Info for BuenaVista

No you don't Icecool. You engage with them and it's very tedious and borderline green box stuff.

On a totally different note, how very dare you call the Trump cultists MAGA morons Nanomat! Everyone knows they are MAGA megamorons.

Here you are Beechnot. This is what The Light is about.

The Light: Inside the UK’s conspiracy theory newspaper that shares violence and hate

https://www.bbc.co.uk/news/uk-65821747

"A UK conspiracy theory newspaper sharing calls for trials and executions of politicians and doctors has links with the British far-right and a German publication connected to a failed coup attempt, the BBC can reveal..."

Some people like that sort of thing. Personally, I think humanity should aim higher.

Thanks for the clarification gmcc & j_t.

There were 19 patients in C1-C4 and today's RNS says "a total of 29 patients with a range of advanced and/or metastatic solid tumours have now been dosed at the clinical trial in sites in the UK and United States" so that'll be 10 in C5. I wonder why so many, given expectation was for 3-6, if DLTs weren't a problem.

Thornogson/Eggy or whatever it is is just a sad idiot without a moral compass.

The market doesn't think an oncology company on AIM could be worth investing in.

Enjoy the low SP whilst it lasts, and you have cash to invest.

Side effects are of two sorts: transient such as nausea, vomitting, diarrhea, hair loss, etc and these may be uncomfortable but the body just needs time to recover; and permanent such as cardiotoxicity with doxorubicin. We've heard that there was no cardiotoxicity in C4. If there are few or no permanent side effects then AVA6000 could be given over many cycles and could become a maintenance therapy, if not a cure, for epithelial (FAP-rich) cancers provided patients can tolerate the transient side effects.

The news in today's RNS is fantastic. However the market hasn't twigged quite what it means, and by 'quite' I mean not at all.

No, it has been an efficacy vs toxicity issue for other cancers that are not treated with doxorubicin.

MHRA gave them the option for up to C7 and 400mg/m².

However Alan has stated that they also have the option to declare a Biologically Effective Dose (BED) if MTD isn't found or doesn't need to be found.

Hopefully they will build weekly cycles into this Phase 1 study as that will have to be tested and proved before it could be included as a treatment option in the clinic. If not done now, it would mean another trial.

Previously, a 'standard' doxorubicin dose was given as 60mg/m² which is why the initial 80mg/m² of AVA6000 was said to be 90% of the 'standard' dose and all calculations of the amount of doxorubicin equivalent were calculated on the basis of {AVA6000 dose} x 54/80 and then quoted by us here as a multiple of the 60mg/m².

However, today, Alan has changed the scale.

310mg/m² is 310x54/80 = 209.25mg/m² doxorubicin equivalent and that is 3.48 times the 60mg/m² dose. However the RNS says "equivalent to 2.7 times the standard dose of doxorubicin".

Well... 209.25mg/m² is 2.79 times the highest administrable dose of doxorubicin, which is 75mg/m² (and 6 x 75 = 450, the maximum lifetime cumulative dose of doxorubicin).

And, to check, the previous dose of 250mg/m² is 168.75mg/m² doxorubicin equivalent, which is 2.25 times the 75mg/m² dose of doxorubicin - the figure given in the RNS for the previous dose.

So... compared to what has gone before, even better than the comparisons with standard doxorubicin look!

Doxorubicin's efficacy vs toxicity profile is weighted towards toxicity for some cancers. Remove the toxicity and...

Looking forward to the no new material information about this at the AGM!

Questions: How much are these patients who are continuing with AVA6000 receiving, and are they getting it 3-weekly or more frequently? That is, do the trial criteria for what is supposed to be a safety and tolerability study continue to apply?

Until the red dot appears here on LSE...

https://www.londonstockexchange.com/news-article/AVCT/completion-of-fifth-dose-escalation-in-ava6000/16007272

WOW!!!!!!!!!!!!!!

...is that it is listed on AIM. Imagine a company aspiring to be the next Roche, but listed on the joke of a market that is AIM. No wonder Avacta isn't being taken seriously. Maybe a question for the AGM could be about listing on NASDAQ or at least the main London market or having the shares tradable in the US.

I'll leave it to others to speculate on the size of the pie. I was more interested in what's in the pie.

Yet there have been absolutely no market notifications...

Question: Is a $1bn doxorubicin market the same as doxorubicin being a $1bn drug? The latter is clear: it is $1bn of sales per annum. However, does the former also include the costs of treating side-effects - everything that needs to be bought when doxorubicin is used?

Secondly, how big is the anthracycline market compared to the doxorubicin market, and could a better tolerated and safer doxorubicin be substituted for the other anthracyclines? Related to that, why and for what are the other anthracyclines used?

Well if your investment in Avacta isn't a problem for you, thank you for your sage advice to others about the rampers. So kindhearted, so caring of you. How about you disappear again for another 8 months? Clink, clink!